Announcements Trials
Browse Landscape

Phase

Phase 3 20Phase 1 6Phase 2 5Phase 2/3 2Phase 1/2 2Phase EARLY_PHASE1 1Phase 4 1

Status

Terminated 2Withdrawn 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Retinoblastoma 1Recurrence 1

Interventions

Magnetic Resonance Spectroscopy 17Cyclophosphamide 16fludarabine 12Specimen Handling 12Fluorodeoxyglucose F18 7pembrolizumab 6X-Rays 6Nivolumab 6Temozolomide 5Radiotherapy 5Immunotherapy, Adoptive 5lenvatinib 4Paclitaxel 4Leukapheresis 4Immune Checkpoint Inhibitors 4Etoposide 4Cisplatin 4Carboplatin 4ruxolitinib 3fluciclovine F-18 3Tirzepatide 3Surgical Procedures, Operative 3Doxorubicin 3Dasatinib 3Cholecalciferol 3Biopsy 368Ga-FAPI 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3tislelizumab 2palbociclib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Recruiting × Topotecan × Clear all
NCT06972602 2025-05-15

High-dose Topotecan for Retinoblastoma With Recurrent or Refractory Vitreous Seed

Eye & ENT Hospital of Fudan University

Phase EARLY_PHASE1 Recruiting
10 enrolled
Other solid neoplasm

Recurrence, Retinoblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡